We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Blood Test Detects Prion Diseases

By LabMedica International staff writers
Posted on 11 Jul 2011
A novel assay has been developed that will rapidly screen blood plasma for variant Creutzfeldt-Jacob disease (vCJD). More...


An integrated antibody-based approach with an improved real-time quaking-induced protein conversion (RT-QuIC) reaction enhanced the detection of vCJD brain tissue diluted into human plasma.

Scientists at the US National Institute of Allergy and Infectious Diseases, (NIAID; Bethesda, MD, USA), collaborated with scientists from Prionics AG, (Schlieren-Zurich, Switzerland), to develop the sensitive bioassay. RT-QuIC, developed only recently, detects the abnormal form of prion protein, which, in purified form, resembles amyloid fibrils. This combined assay, which they call enhanced QuIC (eQuIC), detects approximately 2 attograms (10-18 grams) per mL of proteinase K–resistant prion protein, a 1014-fold dilution, indicating a 10,000-fold increase in sensitivity compared with previously reported methods of vCJD brain tissue detection.

In addition, in early preclinical studies, the eQuIC screening tool has been found to distinguish between plasma and serum samples from scrapie-infected and uninfected hamsters. This rapid and sensitive screening tool that detects prion diseases, also known as transmissible spongiform encephalopathies, would aid in the prevention of prion disease transmission within and between species because animals and people are commonly infected for years before symptoms of the disease appear.

Byron Caughey, PhD, senior investigator in the NIAID Laboratory of Persistent Viral Diseases, said, ""The eQuIC assay in particular provides a practical, high-throughput, and rapid means of testing for amounts of partially protease-resistant form of the host's prion protein that are several orders of magnitude below those typically required to cause prion disease by intracerebral inoculation into animals."

The authors concluded that the remarkable resistance to inactivation of prions relative to other pathogens also makes it important to develop practical assays for prion contamination in a wide variety of materials, such as foods, feeds, transplanted tissues, medical devices, agricultural wastes and by-products, soils, water sources, and other environmental samples. The article was published on May 10, 2011 in the journal mBIO.

Related Links:
US National Institute of Allergy and Infectious Diseases
Prionics AG


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.